top of page
Search

Dendritic Nanogel technology: improve your drug formulations


Over the past few decades and with the advance in nanotechnology, big efforts have been directed toward developing drug delivery systems (DDS) to reduce the side effects of already approved pharmaceuticals. Despite nanocarriers proposing several advantages to treat diseases via site-specific as well as targeted delivery, low solubility, biocompatibility, long-term stability, and cell uptake are still challenges to overcome.


For this reason, Polymer Factory has developed a ready to use and biocompatible Dendritic Nanogel formulation (DNG) that protects small molecules or another encapsulated drug.


The DNG drug delivery platform is based on a degradable block of copolymers with a dendritic-linear hydride configuration. The block of copolymers is composed of linear hydrophilic PEGs and hydrophobic dendritic bis-MPA components. The hydrophobic dendritic constituents contain end-groups which can be modified with hydrophobic, anionic and cationic functionalities or with a fluorescent tag.


Our DNG platform is produced in aqueous conditions via thiol-Ene chemistry which provide control and reproducibility over the nanoparticle formation process resulting in particles with low polydispersity, and a range of sizes between 150-400 nm depending on the length of the hydrophilic core.


DNG formulation presents high stability at room temperature and has the potential to encapsulate, transport, and control the release of cargo (e.g., pharmaceuticals, peptides, and antibiotics).


If you are looking to improve your drug formulation, contact us at info@polymerfactory.com




コメント


bottom of page